AquaBounty Technologies has appointed Colliers as the exclusive agent to market its Pioneer, Ohio property during a strategic review aimed at maximizing shareholder value. The property features valuable infrastructure like a 50-megawatt electrical substation and groundwater permits, attracting potential buyers in power generation, industrial, and data center sectors. AquaBounty plans to engage both industrial and aquaculture companies in discussions but makes no guarantees on transaction outcomes or timing. The company will update shareholders only if significant developments occur.
AquaBounty's Ohio property sale plans provide context for industrial sector activity. For readers following Industrials, here is Pluang's market snapshot as of Sep 15, 2026 18:15 WIB: Out of 75 priced US industrial stocks, 23 rose and 43 fell. Rio Tinto (ADR) traded at USD 96.75, down 0.91%, EHang Holdings Ltd (ADR) at USD 4.47, down 0.89%, and United Airlines Holdings Inc at USD 108.00, down 0.88%.
Graphene Manufacturing Group Ltd. announced that CEO Craig Nicol will join a live fireside chat on September 17, 2026, to discuss recent advances in their G®CELLS graphene battery technology, including impressive long-life cycling data showing 489 ch...
Oracle Corporation reported a record Q1 revenue of $19.3 billion, a 30% increase year-over-year, driven by growth in Cloud Infrastructure and customer prepayments. Despite improved cash flow from prepayments, the company faces risks from high custome...
Shiba Inu (SHIB) has seen a sharp 78% decline in its seven-day moving average of mean exchange outflows, a key metric that previously indicated bullish momentum. This drop means fewer tokens are leaving exchanges, suggesting less movement away from t...
BlackRock has purchased more than $1 billion worth of Bitcoin in the past 20 days, increasing its total Bitcoin holdings to approximately 785,900 BTC valued at around $61 billion. This move highlights strong institutional demand for Bitcoin through B...
Lakefront Biotherapeutics, formerly Galapagos, rebranded and acquired Ouro Medicines' assets with Gilead, creating a new drug development platform. The company has €2.24 billion in liquidity to support clinical trials for gamgertamig, a drug targetin...
